New Study Improves Opioid Withdrawal Treatment for Newborns

A new NIH-funded clinical trial is changing how doctors approach medical detox for one of the most vulnerable patients in the opioid crisis: newborns.

The research, published in JAMA, finds that matching opioid withdrawal treatment to each infant’s actual symptoms, rather than following a fixed dosing schedule, gets babies off medication faster and home sooner.

For pregnant women receiving medication-assisted treatment, the findings are directly relevant to birth planning and neonatal care.

What Is Neonatal Opioid Withdrawal Syndrome

Neonatal opioid withdrawal syndrome (NOWS), sometimes still referred to as neonatal abstinence syndrome (NAS), occurs when a baby is born having been exposed to opioids in the womb and then experiences withdrawal after birth.

It is a direct consequence of opioid use during pregnancy, including use of FDA-approved medications like buprenorphine and methadone that are prescribed as part of medication-assisted treatment for opioid use disorder.

According to 2021 estimates, one baby is diagnosed with NOWS every 24 minutes in the United States, or more than 59 newborns diagnosed every day.

Symptoms can include tremors, excessive crying, irritability, and problems with sleeping, feeding and breathing. In moderate to severe cases, medical treatment with opioid medication is required to manage the withdrawal safely.

NOWS is not a reason to avoid MAT during pregnancy. Medical consensus, including from ACOG and SAMHSA, consistently holds that untreated opioid use disorder poses far greater risks to mother and baby than the manageable, treatable condition of neonatal withdrawal.

The OPTimize NOW Clinical Trial

The NIH-funded OPTimize NOW trial compared a symptom-based dosing approach to the traditional scheduled opioid taper approach in 383 infants with moderate to severe NOWS, all of whom were also cared for under the family-centered Eat, Sleep, Console (ESC) approach.

One group of 194 infants received scheduled opioids tapered after withdrawal symptoms were controlled. The other group of 189 infants received opioid medication only when their withdrawal signs reached a prespecified threshold, with additional doses given only if severity crossed that threshold again. Established guardrails prevented undertreatment.

Babies in the symptom-based dosing group were ready to go home two days earlier than those receiving scheduled dosing, and also stopped medication sooner.

Two days may not sound significant in isolation. In a neonatal intensive care unit, it represents a meaningful reduction in hospital stress for the infant, measurable cost savings, and earlier family bonding, all of which matter for the long-term developmental trajectory of a baby already navigating a difficult start.

Why Medical Detox Matters in the Neonatal Context

Corresponding author Lori Devlin, D.O., a professor of pediatrics at the University of Louisville and Norton Children’s Neonatology, explained the core principle: by matching treatment to disease severity, the approach accelerates recovery and minimizes drug exposure.

Co-author Augusto Schmidt, M.D., Ph.D., a program officer at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, described the findings as a simple and powerful way to get babies home faster, which is best for their family and for their own development.

The study was conducted under the NIH HEAL (Helping to End Addiction Long-term) Initiative and published in JAMA. Since the trial, several hospitals involved in the study have adopted the symptom-based strategy, and the authors believe results may inform broader adoption.

One important clinical note: researchers did not find that symptom-based dosing conferred the same benefits to infants cared for under the traditional Finnegan scoring approach rather than ESC, meaning that care model matters alongside dosing strategy.

What This Means for Women on MAT

For women currently receiving buprenorphine or methadone as part of medication-assisted treatment for opioid use disorder, this research reinforces several practical points:

MAT should not be stopped during pregnancy. Abrupt discontinuation of buprenorphine or methadone carries serious risks including relapse, overdose, and miscarriage. NOWS, while requiring medical management, is an expected and treatable condition, not a reason to avoid evidence-based treatment.

Choosing the right birth facility matters. The OPTimize NOW findings suggest that neonatal outcomes are meaningfully affected not just by medication choice but by the care model hospitals use. When possible, women on MAT should seek facilities familiar with the Eat, Sleep, Console approach and symptom-based dosing protocols.

Continuity of care is critical. The postpartum period carries elevated overdose and mental health risk for women with opioid use disorder. Ensuring that MAT is continued through delivery and beyond is a key component of keeping both mother and baby safe.

Important Notice for Pregnant Women With Opioid Use Disorder

Do NOT stop buprenorphine, methadone, or other MAT medications during pregnancy without direct guidance from your prescribing physician. Abrupt discontinuation can cause opioid withdrawal, which carries serious risks to both mother and fetus including miscarriage, preterm labor and overdose.

Neonatal opioid withdrawal syndrome is a manageable, treatable condition. Continuing MAT under medical supervision is the safest course for both you and your baby.

Finding Medical Detox Programs for Opioid Dependence

If you or someone you love is dependent on opioids and pregnant, or planning to become pregnant, connecting with a medically supervised detox and MAT program before or during pregnancy is critical. Programs that specialize in perinatal addiction care can coordinate obstetric and addiction medicine services under one care model.

Never attempt opioid, alcohol, or benzodiazepine detox without medical supervision. Withdrawal from these substances without proper oversight carries serious, life-threatening risks.

Search detox.com’s directory to find verified detox centers in your area. You can call 800-996-6135(Sponsored) to speak with a treatment advisor to start your recovery today.